Investigational Oral GLP-1 Medication: Orforglipron

Consultations offered at our three convenient locations in Austin, TX, San Antonio, TX and Westlake Hills, TX

Orforglipron is not currently available for use or prescription at Austin Plastic Surgeon. It is an investigational medication and is not FDA-approved.

Oral GLP-1 Medication: Orforglipron Austin, TX

Orforglipron is an investigational oral glucagon-like peptide-1 (GLP-1) medication currently being explored for its potential weight loss benefits. (1)

For some people, despite their best efforts to practice healthy lifestyle habits such as adopting a proper diet and exercise regimen, it can still be difficult to lose weight. As such, an increasing number of individuals are seeking effective solutions for weight management, appetite regulation, and enhancing insulin sensitivity.

Orforglipron belongs to a class of drugs known as GLP-1 receptor agonists. GLP-1 medications such as orforglipron play a vital role in managing weight and aiding diabetes therapy. Other medications in this class include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). These medications have recently expanded in popularity because they offer impressive weight loss results. The Austin Plastic Surgeon team specializes in numerous weight loss treatments and can help you reach your goals.

Orforglipron is not yet avialable to the public. However, Austin Plastic Surgeon offers several different weight loss treatments, which you can explore by scheduling a personal consultation online or calling one of our three locations:

About Orforglipron

Orforglipron is an oral GLP-1 receptor agonist that is being researched for its ability to deliver powerful weight loss results without requiring injections. Currently, this medication is pending FDA approval and is not yet available for public use outside of clinical trials. With this established, orforglipron is designed to mimic a naturally occurring hormone that regulates appetite, slows digestion, and helps control blood sugar. Early clinical trials have shown promising weight loss outcomes with orforglipron. (2)

By targeting the same pathways as injectable GLP-1 drugs, orforglipron ultimately intends to offer the benefits of these treatments with added convenience and improved adherence. In doing so, the goal of orforglipron is to create a modern, low-barrier therapy that supports meaningful weight reduction, improved energy, and metabolic balance.

If the Medication Becomes Available, Who Will Be Ideal Candidates?

Weight loss treatments in general can appeal to a wide array of candidates. If approved, orforglipron may be suitable for individuals who:

  • Are overweight or obese and have had limited success with diet and exercise alone
  • Prefer an oral alternative to injectable medications
  • Have weight-related health conditions such as prediabetes or insulin resistance
  • Are looking to maintain their results following a body contouring or bariatric procedure
  • Are in good general health and willing to commit to lifestyle changes during treatment

Personal Consultation

Your journey toward taking full control over your weight will begin with a one-on-one consultation at Austin Plastic Surgeon. During this visit, one of our expert weight loss specialists will take the time to sit down with you and discuss your goals. They will review your medical history, discuss your weight loss objectives, and assess your overall health profile. While we do not offer orforglipron currently, we offer injectable weight loss medications. If eligible, you will receive a personalized treatment plan and education about what to expect throughout the process.

Your consultation will allow you to ask questions, express concerns, and learn about your options. Our staff may also recommend additional or alternative treatments that they feel are appropriate to help you with your weight loss journey.

Schedule your consultation by contacting Austin Plastic Surgeon online or by calling one of our three locations:

Treatment

One of the reasons why there is a great deal of excitement surrounding orforglipron as a future weight loss supplement is largely because the treatment process for this medication would be simple. In clinical trials, orforglipron has been administered as a once-daily oral tablet, typically taken in the morning on an empty stomach.

Corresponding Procedures

After massive weight loss, many patients consider procedures to address excess skin and stubborn fat. These may include liposuction or body contouring procedures. Austin Plastic Surgeon also offers treatments such as bioidentical hormone therapy and other weight loss treatments that may enhance your results.

Our team will help you explore complementary options based on your goals and current progress.

If you are looking for the latest in cutting-edge weight loss treatments, contact Austin Plastic Surgeon online to schedule a personal consultation or give us a call at one of our three locations:

FAQ

What is orforglipron?

Orforglipron is an investigational oral GLP-1 receptor agonist being studied for its potential to reduce appetite, regulate blood sugar, and support weight loss.

How soon are the results of a orforglipron regimen apparent?

Orforglipron is not yet available to the public. In early trials, some participants began noticing effects within 4–8 weeks.

Are there any side effects of GLP-1s?

Some patients experience nausea, bloating, or fatigue during the adjustment period. These symptoms typically subside with continued use as your body adjusts to the medication.

References

  1. Dutta D, Lakshmi Nagendra, Anne B, Kumar M, Sharma M, A. B. M. Kamrul‐Hasan. Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis. Obesity science & practice. 2024;10(2). doi:https://doi.org/10.1002/osp4.743
  2. Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England Journal of Medicine. 2023;389(10). doi:https://doi.org/10.1056/nejmoa2302392
  3. Wiley TMP, Poirier P, Burke LE, et al. Obesity and Cardiovascular disease: a Scientific Statement from the American Heart Association. Circulation. 2021;143(21):984-1010. doi:https://doi.org/10.1161/cir.0000000000000973